Diagnostic device for conducting a panel of serological tests based on proteins and antibodies outside the central laboratories.

Picodya has developed the B-Matrix™ system - a diagnostic device for conducting a panel of serological tests based on proteins and antibodies outside the central laboratories. This will be adapted by the distribution of many devices as a national system for monitoring the serological response of the system (SARS, Coronavirus, influenzas) in the population for infectious respiratory diseases. This will enable the administration of serological antibodies testing of the population on a large scale and will provide real time and reliable information to decision-makers on a regular basis regarding the spread of the pandemic and the development of immunity in the population. The system will serve as a solution that will supplement the RNA/DNA testing using RT PCR devices in the laboratories, and increase the scale of inexpensive testing, by distributing the B-Matrix™ device to key locations (central labs at hospitals, community clinics, army bases, etc.) which will simultaneously measure the response to dozens of viral antigens based on tests that were conducted in the field, by extracting a number of drops of blood from subjects. The results that will be received from dozens of tests per hour will be transferred to the National Information Base. The company is aided by consultants and collaborates with leading researchers from Israeli research institutes and hospitals.